Literature DB >> 16415794

The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.

Nelson G Ordóñez1.   

Abstract

As both mesotheliomas and squamous carcinomas can present a wide variety of morphological patterns, they can on occasion be confused. Recently, some groups of investigators have called attention to the difficulties that sometimes exist in distinguishing between these malignancies and the need to define a panel of markers that can assist in reaching the correct diagnosis. The aim of the present study is to compare the value of the various immunohistochemical markers currently available for the diagnosis of mesothelioma and squamous carcinoma of the lung. A total of 30 epithelioid pleural mesotheliomas exhibiting a solid or predominantly solid pattern, and 30 nonkeratinizing squamous carcinomas of the lung were investigated for the expression of the following markers: podoplanin, calretinin, mesothelin, WT1, keratin 5/6, keratin 7, p63, carcinoembryonic antigen (CEA), MOC-31, Ber-EP4, B72.3, BG-8 (Lewis(y)), leu-M1 (CD15), and thyroid transcription factor-1 (TTF-1). All 30 (100%) of the mesotheliomas reacted for calretinin, mesothelin and keratin 7, 93% each for podoplanin, WT1 and keratin 5/6, 13% for Ber-EP4, 7% each for p63, MOC-31 and BG-8, and 0% for B72.3, CEA, leu-M1 and TTF-1. All 30 (100%) of the squamous carcinomas were positive for p63 and keratin 5/6, 97% for MOC-31, 87% for Ber-EP4, 80% for BG-8, 77% for CEA, 57% for keratin 7, 40% for calretinin and B72.3, 30% for leu-M1, 27% for mesothelin, 15% for podoplanin, and 0% for WT 1 and TTF-1. After analyzing the results, it is concluded that from a practical point-of-view, a combination of two positive mesothelioma markers (WT1 and calretinin or mesothelin) with two negative mesothelioma markers (p63 and MOC-31) would allow the differential diagnosis to be established between epithelioid mesotheliomas and squamous carcinomas of the lung in nearly all instances.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415794     DOI: 10.1038/modpathol.3800544

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  25 in total

1.  Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

Authors:  Hector Alvarez; Pamela Leal Rojas; Ken-Tye Yong; Hong Ding; Gaixia Xu; Paras N Prasad; Jean Wang; Marcia Canto; James R Eshleman; Elizabeth A Montgomery; Anirban Maitra
Journal:  Nanomedicine       Date:  2008-08-08       Impact factor: 5.307

Review 2.  Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains.

Authors:  Halliday A Idikio
Journal:  Int J Clin Exp Pathol       Date:  2009-11-25

3.  Differentiating a large abdominal cystic lymphangioma from multicystic mesothelioma: report of a case.

Authors:  Hiroshi Nagata; Yutaka Yonemura; Emel Canbay; Haruaki Ishibashi; Makoto Narita; Makio Mike; Nobuyasu Kano
Journal:  Surg Today       Date:  2013-06-27       Impact factor: 2.549

4.  Improving the Accuracy of Mesothelioma Diagnosis in China.

Authors:  Zhenying Guo; Michele Carbone; Xing Zhang; Dan Su; Wenyong Sun; Jianlin Lou; Zhibin Gao; Dichu Shao; Junqiang Chen; Gu Zhang; Jinlin Hu; Kaiyan Chen; Fang Wang; Harvey I Pass; Herbert Yu; Andrea Napolitano; Haining Yang; Weimin Mao
Journal:  J Thorac Oncol       Date:  2016-12-19       Impact factor: 15.609

5.  Conjunctival 'mucoepidermoid carcinoma' revisited: a revision of terminology, based on morphologic, immunohistochemical and molecular findings of 14 cases, and the 2018 WHO Classification of Tumours of the Eye.

Authors:  Hardeep S Mudhar; Tatyana Milman; Paul J L Zhang; Carol L Shields; Ralph C Eagle; Sara E Lally; Jerry A Shields; Sachin M Salvi; Paul A Rundle; Jennifer Tan; Ian G Rennie
Journal:  Mod Pathol       Date:  2020-01-13       Impact factor: 7.842

6.  Overview of Lung Cancer Immunotherapy.

Authors:  Miguel F Sanmamed; Iñaki Eguren-Santamaria; Kurt A Schalper
Journal:  Cancer J       Date:  2020 Nov/Dec       Impact factor: 3.360

Review 7.  The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.

Authors:  Greta Alì; Rossella Bruno; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

8.  The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.

Authors:  Nurhan Sahin; Ayse Nur Akatli; Muhammet Reha Celik; Hakkı Ulutas; Emine Turkmen Samdanci; Cemil Colak
Journal:  Pathol Oncol Res       Date:  2016-10-19       Impact factor: 3.201

9.  Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update.

Authors:  Dongfeng Tan; Dani S Zander
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

10.  Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy.

Authors:  Christian Wüthrich; Yi Min Cheng; Jeffrey T Joseph; Santosh Kesari; Curt Beckwith; Edward Stopa; Jeanne E Bell; Igor J Koralnik
Journal:  J Neuropathol Exp Neurol       Date:  2009-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.